Breadcrumb navigation

White PaperNEW

-Towards the realization of AI drug development-
Comprehensive process workflow for the commercial use of personalized cancer vaccines


NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

Outline

  1. A comprehensive process workflow that can be applied to a wide range of processes
  2. Important perspectives for consideration in the workflow
  3. Advanced technologies that will contribute to the realization of the workflow

publication_thumbnail

Featured publicationNEW

AACR2024: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV-negative Head and Neck cancers

  • Abstract number: LB401
  • Session title: Late-Breaking Research: Clinical Research 3
  • Authors: A. Lalanne, C. Jamet, J.-P. Delord, C. Ottensmeier, C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M. Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke, N. Yamagata, Y. Tanaka, K. Onoguchi, I. Pait, B. Malone, O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K. Bendjama, O. Lantz;

Links: new windowPDF of actual poster

publication_thumbnail

Publication / Presentation

Jul 27, 2023
Y Yamashita, "Utilization of Artificial Intelligence in vaccine development." 2023; The 39th Annual Meeting of the Japan Society of Drug Delivery System
May 24, 2023
A Kitamura, "NEC's AI Drug Development Initiatives." 2023; 72nd SPSJ Annual Meeting
Jul 23, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 57th Annual Meeting of Liver Cancer Study Group of Japan
Jun 19, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 13th Annual Meeting of Japanese Society of Immunotherapy for Hematological Disorders
May 23, 2021
Y Yamashita, K Bendjama, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 18th Annual Meeting of Japan Research Association for Immunotherapeutics
Apr 16, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; Bring Innovation in the Pharmaceutical Industry
Mar 5, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 4th Social Smart Dental Hospital Symposium
Nov 29, 2019
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2019; The 32nd Annual Meeting of the Japan Society for Biological Therapy
Aug 23, 2019

K Onoue, Y Yamashita, B Malone, Y Tanaka, B Grellier, K Bendjama, K Machida, and K Udaka, "Evaluation of HLA-peptide binding prediction method." 2019; The 23rd Annual Meeting of Japanese Association of Cancer Immunology

Research Paper

NEC Labs Europe
Digital Health is a rapidly growing business for the NEC Group. In the Biomedical AI group, we consider challenges from prevention, diagnosis, and through treatment.

Read publication

NEC Labs America
Machine learning is the key technology for data analytics and artificial intelligence. We have been at the forefront of developments in such areas as deep learning, support vector machines and so on for over a decade.

Read publication